<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077217</url>
  </required_header>
  <id_info>
    <org_study_id>CZH0010</org_study_id>
    <nct_id>NCT03077217</nct_id>
  </id_info>
  <brief_title>Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy</brief_title>
  <official_title>Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have been showed that rifaximin can improve cognitive functions, driving&#xD;
      simulator performance and health-related quality of life in patients with minimal hepatic&#xD;
      encephalopathy. The aim of this prospective randomized open controlled study was to evaluate&#xD;
      the efficacy and safety of rifaximin at different doses for the treatment of covert hepatic&#xD;
      encephalopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients showing covert hepatic encephalopathy reversal</measure>
    <time_frame>up to 6 months</time_frame>
    <description>the percentage of patients showing covert hepatic encephalopathy reversal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>health-related quality of life improvement</measure>
    <time_frame>up to 6 month</time_frame>
    <description>complete the questionnaire &quot;sickness impact profile&quot;</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Covert Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>the high-dose rifaximin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The high-dose rifaximin group was given rifaximin 1200 mg/day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the low-dose rifaximinl group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The low-dose rifaximin group was given rifaximin 800 mg/day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group didn't receive rifaximin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy</description>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_label>the high-dose rifaximin</arm_group_label>
    <arm_group_label>the low-dose rifaximinl group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients agreed to sign the informed consents&#xD;
&#xD;
          2. Patients aged 18-70 years，males or females&#xD;
&#xD;
          3. Patients who were diagnosed with occult hepatic encephalopathy by PHES and Stroop&#xD;
             tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to rifamycin/rifamutin/rifampin/rifapentine&#xD;
&#xD;
          2. Current or recent (&lt;3 month) use of alcohol or can't stop drinking during the study&#xD;
             period&#xD;
&#xD;
          3. Use of antibiotics within last 6 weeks&#xD;
&#xD;
          4. Use of lactulose/lactitol, probiotics, L-ornithine-L-aspart，zinc，metronidazole,&#xD;
             neomycin, or rifaximin within last 6 weeks&#xD;
&#xD;
          5. Infection or gastrointestinal hemorrhage within last 6 weeks&#xD;
&#xD;
          6. Use of psychoactive drugs within last 6 weeks&#xD;
&#xD;
          7. Occurred overt hepatic encephalopathy within last 3 months&#xD;
&#xD;
          8. history of portosystemic shunt surgery or transjugular intrahepatic portosystemic&#xD;
             shunt&#xD;
&#xD;
          9. Poor vision, color blindness or motor defects that interfere with the performance of&#xD;
             psychometric tests&#xD;
&#xD;
         10. Other non-controllable neurological or psychiatric problems which may affect cognitive&#xD;
             function such as Alzheimer's disease, Parkinson's disease or schizophrenia&#xD;
&#xD;
         11. Conformed or highly suspicious diagnosis of liver malignant tumors&#xD;
&#xD;
         12. Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
         13. Uncontrolled hypertension, diabetes or other serious cardiac and pulmonary diseases&#xD;
&#xD;
         14. White blood cell count&lt;1×10^9/L&#xD;
&#xD;
         15. Pregnancy and breastfeeding&#xD;
&#xD;
         16. Participated in other drug clinical trials within 3 months&#xD;
&#xD;
         17. The researchers thought it was not suitable for this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Wei-Fen Xie</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>covert hepatic encephalopathy</keyword>
  <keyword>low-dose rifaximin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

